User profiles for Steven A. Eschrich
Steven EschrichMoffitt Cancer Center Verified email at moffitt.org Cited by 15786 |
Radiomics: the process and the challenges
“Radiomics” refers to the extraction and analysis of large amounts of advanced quantitative
imaging features with high throughput from medical images obtained with computed …
imaging features with high throughput from medical images obtained with computed …
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
Background Despite its common use in cancer treatment, radiotherapy has not yet entered
the era of precision medicine, and there have been no approaches to adjust dose based on …
the era of precision medicine, and there have been no approaches to adjust dose based on …
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation
SA Eschrich, J Pramana, H Zhang, H Zhao… - International Journal of …, 2009 - Elsevier
PURPOSE: Development of a radiosensitivity predictive assay is a central goal of radiation
oncology. We reasoned a gene expression model could be developed to predict intrinsic …
oncology. We reasoned a gene expression model could be developed to predict intrinsic …
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis
Background Despite advances in cancer genomics, radiotherapy is still prescribed on the
basis of an empirical one-size-fits-all paradigm. Previously, we proposed a novel algorithm …
basis of an empirical one-size-fits-all paradigm. Previously, we proposed a novel algorithm …
Validation of a radiosensitivity molecular signature in breast cancer
SA Eschrich, WJ Fulp, Y Pawitan, JA Foekens… - Clinical Cancer …, 2012 - AACR
Purpose: Previously, we developed a radiosensitivity molecular signature [radiosensitivity
index (RSI)] that was clinically validated in 3 independent datasets (rectal, esophageal, and …
index (RSI)] that was clinically validated in 3 independent datasets (rectal, esophageal, and …
Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin
…, MK Washington, JT Roland, AL Means, SA Eschrich… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: Mutational inactivation of adenomatous polyposis coli (APC) is an
early event in colorectal cancer (CRC) progression that affects the stability and increases the …
early event in colorectal cancer (CRC) progression that affects the stability and increases the …
Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy
…, YA Abuodeh, JM Frakes, SA Eschrich… - International Journal of …, 2016 - Elsevier
Purpose/Objectives Evidence from the management of oligometastases with stereotactic body
radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We …
radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We …
[HTML][HTML] Iterative rank-order normalization of gene expression microarray data
Background Many gene expression normalization algorithms exist for Affymetrix GeneChip
microarrays. The most popular of these is RMA, primarily due to the precision and low noise …
microarrays. The most popular of these is RMA, primarily due to the precision and low noise …
Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer
…, AO Naghavi, EE Harris, SA Eschrich - International Journal of …, 2015 - Elsevier
Purpose Recently, we developed radiosensitivity (RSI), a clinically validated molecular signature
that estimates tumor radiosensitivity. In the present study, we tested whether integrating …
that estimates tumor radiosensitivity. In the present study, we tested whether integrating …
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells
…, AA Beg, U Rix, SA Eschrich… - Proceedings of the …, 2013 - National Acad Sciences
TANK-binding kinase 1 (TBK1) has emerged as a novel therapeutic target for unspecified
subset of lung cancers. TBK1 reportedly mediates prosurvival signaling by activating NF-κB …
subset of lung cancers. TBK1 reportedly mediates prosurvival signaling by activating NF-κB …